Fentanyl sublingual spray was associated with improvements in a number of pain and adverse event categories in a cohort of patients with several types of cancer, according to findings presented at the Oncology Nursing Society Annual Congress.
Michelle Rhiner, RN, of Loma Linda University in New York, and colleagues conducted a multicenter, randomized, double blind, placebo-controlled study to determine whether fentanyl sublingual spray adequately treats cancer pain or affects quality of life of patients with cancer. Full Story »
Personalize your page!
Register for Healio to get content tailored to your specialty and areas of interest.
It’s FREE and only takes one minute.